Bharat Biotech and GSK Unite for Groundbreaking Shigellosis Vaccine
Bharat Biotech has partnered with GSK to develop a Shigellosis vaccine. The altSonflex1-2-3 candidate is one of the most advanced globally. With no existing licensed Shigella vaccine and rising antimicrobial resistance, Bharat Biotech aims to advance its development through clinical trials and large-scale manufacturing.
- Country:
- India
Bharat Biotech announced a strategic partnership with GSK to develop a pioneering vaccine for Shigellosis, a severe bacterial diarrhoeal condition.
The altSonflex1-2-3 vaccine candidate, initially developed by GSK, is making strides with Bharat's collaboration, standing out amongst the most advanced Shigella vaccines worldwide.
The initiative is crucial due to the absence of a licensed Shigella vaccine and mounting antimicrobial resistance. Bharat Biotech will oversee further development, including Phase 3 trials and mass production, with GSK supporting funding and commercial strategies.
(With inputs from agencies.)
Advertisement
ALSO READ
India-Nepal Collaboration Sets Stage for New Agricultural Centre
Powering Syria's Future: A $7 Billion Global Collaboration
Viksit Krishi Sankalp Abhiyan: Empowering Farmers through Scientific Collaboration
Tightening Borders: India-US Collaboration on Deportation and Visa Scrutiny
Steel Giants Unite: A New Era for U.S. and Japanese Collaboration
Google News